Medical - Devices
Compare Stocks
2 / 10Stock Comparison
TNON vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
TNON vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Devices |
| Market Cap | $8M | $112.69B |
| Revenue (TTM) | $3M | $25.12B |
| Net Income (TTM) | $-13M | $3.25B |
| Gross Margin | 52.4% | 63.5% |
| Operating Margin | -405.2% | 22.4% |
| Forward P/E | — | 19.6x |
| Total Debt | $428K | $14.86B |
| Cash & Equiv. | $7M | $4.01B |
TNON vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Tenon Medical, Inc. (TNON) | 100 | 0.0 | -100.0% |
| Stryker Corporation (SYK) | 100 | 122.0 | +22.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TNON vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TNON is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 11.9%, EPS growth 83.6%, 3Y rev CAGR 173.6%
- Lower volatility, beta 1.08, Low D/E 7.2%, current ratio 4.39x
- 11.9% revenue growth vs SYK's 11.2%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- 187.1% 10Y total return vs TNON's -100.0%
- Beta 0.55, yield 1.1%, current ratio 1.89x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.9% revenue growth vs SYK's 11.2% | |
| Quality / Margins | 12.9% margin vs TNON's -396.3% | |
| Stability / Safety | Beta 0.55 vs TNON's 1.08 | |
| Dividends | 1.1% yield; 34-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -22.5% vs TNON's -31.2% | |
| Efficiency (ROA) | 6.9% ROA vs TNON's -114.6%, ROIC 11.4% vs -290.8% |
TNON vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TNON vs SYK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
SYK leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 7768.6x TNON's $3M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to TNON's -4.0%. On growth, TNON holds the edge at +32.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3M | $25.1B |
| EBITDAEarnings before interest/tax | -$13M | $6.3B |
| Net IncomeAfter-tax profit | -$13M | $3.2B |
| Free Cash FlowCash after capex | -$11M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +52.4% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -4.1% | +22.4% |
| Net MarginNet income ÷ Revenue | -4.0% | +12.9% |
| FCF MarginFCF ÷ Revenue | -3.5% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +32.2% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.0% | +56.0% |
Valuation Metrics
TNON leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $8M | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $2M | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.07x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.36x |
| EV / EBITDAEnterprise value multiple | — | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 2.54x | 4.49x |
| Price / BookPrice ÷ Book value/share | 0.15x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | 26.31x |
Profitability & Efficiency
SYK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-191 for TNON. TNON carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), SYK scores 6/9 vs TNON's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -190.8% | +15.0% |
| ROA (TTM)Return on assets | -114.6% | +6.9% |
| ROICReturn on invested capital | -290.8% | +11.4% |
| ROCEReturn on capital employed | -2.5% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.07x | 0.66x |
| Net DebtTotal debt minus cash | -$6M | $10.8B |
| Cash & Equiv.Liquid assets | $7M | $4.0B |
| Total DebtShort + long-term debt | $428,000 | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -404.88x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $4 for TNON. Over the past 12 months, SYK leads with a -22.5% total return vs TNON's -31.2%. The 3-year compound annual growth rate (CAGR) favors SYK at 1.8% vs TNON's -82.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -23.0% | -15.2% |
| 1-Year ReturnPast 12 months | -31.2% | -22.5% |
| 3-Year ReturnCumulative with dividends | -99.5% | +5.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | +21.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -82.9% | +1.8% |
Risk & Volatility
SYK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than TNON's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SYK currently trades 72.7% from its 52-week high vs TNON's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.55x |
| 52-Week HighHighest price in past year | $2.48 | $404.87 |
| 52-Week LowLowest price in past year | $0.64 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +30.2% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 120K | 2.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $403.69 |
| # AnalystsCovering analysts | — | 50 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | 34 |
| Dividend / ShareAnnual DPS | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
SYK leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TNON leads in 1 (Valuation Metrics).
TNON vs SYK: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TNON or SYK a better buy right now?
For growth investors, Tenon Medical, Inc.
(TNON) is the stronger pick with 11. 9% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TNON or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.
5%, compared to -100. 0% for Tenon Medical, Inc. (TNON). Over 10 years, the gap is even starker: SYK returned +187. 1% versus TNON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TNON or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus Tenon Medical, Inc. 's 1. 08β — meaning TNON is approximately 97% more volatile than SYK relative to the S&P 500. On balance sheet safety, Tenon Medical, Inc. (TNON) carries a lower debt/equity ratio of 7% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — TNON or SYK?
By revenue growth (latest reported year), Tenon Medical, Inc.
(TNON) is pulling ahead at 11. 9% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Tenon Medical, Inc. grew EPS 83. 6% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, TNON leads at 173. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TNON or SYK?
Stryker Corporation (SYK) is the more profitable company, earning 12.
9% net margin versus -417. 2% for Tenon Medical, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -420. 1% for TNON. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TNON or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. TNON does not pay a meaningful dividend and should not be held primarily for income.
07Is TNON or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, TNON: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TNON and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK pays a dividend while TNON does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.